摘要
目的：实施奥曲肽致低血糖的自动监测,并评价药源性低血糖模块的功能。方法：采用回顾性分析方法,利用“医疗机构ADE主动监测与智能评估警示系统”对2016年1–6月我院使用醋酸奥曲肽注射液的住院患者进行自动监测,对系统报警病例进行人工甄别,并对监测数据结果进行分析比较。结果：共监测950例患者,其中自动报警26例,人工甄别为阳性12例,ADR发生率范围为1.26%-1.56%,与说明书报道结果相符;发生药源性低血糖的风险因素为“罹患胰腺相关疾病”患者。结论：奥曲肽致低血糖发生率常见,使用时应密切监测患者血糖水平;专项软件系统中药源性低血糖模块能够较为准确的反映临床用药人群发生ADR的真实情况,为药品安全风险防控提供参考和帮助。
Objective： To investigate the hypoglycemia induced by octreotide acetate injection, evaluate the performance of hypoglycemia module. Methods： The retrospective analysis was used to do automatic monitoring on inpatients using of octreotide acetate injection from January to June in 2016 detected by the intelligence assessment warning system for ADE. We manual screened the cases which selected by system, and analyzed the monitoring data. Results： A total of 950 cases using octreotide acetate injection were automatically monitored. There were 26 cases of automatic alarm, in which 12 cases were positive by artificial evaluation. The incidence rate of adverse drug reactions was between 1.26% - 1.56%, which was in conformity with the specification. People with pancreatic disease had the risk factors for hypoglycemia. Conclusion： Hypoglycemia induced by octreotide is common, and patient＇s blood glucose levels should be monitored closely; hypoglycemia module can accurately reflect the real situation of ADR in clinical and make sure of drug safety.
出处
《中国药物应用与监测》
CAS
2016年第5期309-311,共3页
Chinese Journal of Drug Application and Monitoring
基金
2014年全军后勤科研重点项目(BWS14R039)
关键词
奥曲肽
低血糖
药品不良反应
自动监测
Octreotide
Hypoglycemia
Adverse drug reaction
Automatic monitoring
